HormoneInvestigational

Tabimorelin

Oral

Overview

Tabimorelin is an orally active synthetic ghrelin mimetic and selective GHS-R1a agonist developed to stimulate growth hormone release. Unlike peptide analogues, tabimorelin was designed as a small molecule with improved oral bioavailability and stability.

Mechanism of Action

The therapeutic rationale centered on treating frailty, functional decline in the elderly, and conditions associated with growth hormone deficiency..

Research Summary & Key Findings

Phase 2 clinical trials evaluated tabimorelin in elderly hip fracture patients and in sarcopenia, with results published in the Journal of Clinical Endocrinology and Metabolism in 2007 showing increases in growth hormone and IGF-1 levels. Development was discontinued before Phase 3 completion, and no regulatory approval was pursued. Evidence supported hormonal activity but did not establish clinical benefit in functional outcomes.

Clinical Status

Investigational

Tabimorelin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Oral

Related Peptides in Hormone

CJC-1295

In Clinical Trials

A synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...

View details

Ipamorelin

In Clinical Trials

A highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...

View details

Sermorelin

FDA Approved

A synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...

View details

Tesamorelin (Egrifta)

FDA Approved

A synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification...

View details

Find a Provider

Find a verified provider who offers Tabimorelin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Tabimorelin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.